Latest United States News

Nico Resources has completed about 70% of a 6,000-metre infill drilling program at its Wingellina nickel-cobalt project, with initial assays expected in November. The technical progress comes as nickel and cobalt prices weaken and a proposed downstream partnership remains non-binding.

Transurban has clarified that the I-24 Southeast Choice Lanes award involves US$21 billion in present-value payments to Tennessee, rather than the previously published US$24.8 billion headline figure. The concession also includes revenue-sharing provisions that could increase the state’s take if toll revenues or returns exceed agreed thresholds.

OD6 Metals has identified interpreted fluorspar extensions beneath cover and at depth at its Quinn project in Nevada, including a potential Mammoth target extending more than 500 metres below surface. The results sharpen the company’s drill targets ahead of a proposed early-2027 maiden campaign, but remain indirect geophysical evidence requiring confirmation.

Iluka Resources delivered higher contracted zircon pricing and reduced mineral sands net debt in the September quarter, while the Eneabba rare earths refinery reached 65% construction completion. The update also showed the execution risks still attached to Balranald and a prolonged shutdown of synthetic rutile capacity.

Deep Yellow has pushed back its targeted fourth-quarter Final Investment Decision for the Tumas uranium project, citing unfavourable equity market conditions. The delay comes as engineering reaches 85%, construction works begin and cash falls to A$144.7 million.

Venari Minerals has funded the next stage of its Red Mountain lithium project after raising $6.1 million, while drilling and permitting advance in Nevada. The company is also testing whether strontium and magnesium can add value beyond lithium carbonate, although commercial recovery remains unproven.

OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.

Nova Eye Medical delivered 30% year-on-year sales growth in the September quarter, alongside positive operating cash flow and EBITDA. The company confirmed FY27 guidance, but is still seeking to replace a related-party funding facility carrying 15% interest.

Kelsian Group has entered FY27 after a record financial year, the $149.9 million sale of its Tourism Portfolio and a sharp reduction in leverage. But the transport operator is also awaiting an independent review into a fatal June bus incident as it pursues fresh international growth.

Botanix’s Sofdra prescriptions rose 5.3% in the September quarter, but flat net revenue and a sharp cash decline have forced a major reset. The company is targeting a roughly 50% reduction in operating expenses while assessing licensing, acquisitions and broader strategic transactions.

NeuroScientific Biopharmaceuticals has secured favourable US FDA feedback on its planned StemSmart Phase 2 trial for refractory Crohn’s disease, while appointing a clinical research partner and advancing manufacturing validation. The company enters the next phase with $3.91 million in cash and a targeted trial start by the end of 2026.

Ioneer has pushed the timing of a final investment decision for its Rhyolite Ridge lithium-boron project to an unspecified date, as strategic partner discussions extend into the December quarter. The company ended September with US$54.55 million in cash and reported 12.8 quarters of funding on its current quarterly outgoings.